Merck & Co., Inc.: Company Overview
The most valuable drug in the history of the pharmaceutical industry began its life as an also-ran. When Merck & Co. Licensed pembrolizumab — the compound that would eventually become Keytruda — from Organon in 2009 for a modest upfront payment, the PD-1 pathway it targeted was considered a promising but scientifically crowded corner of immuno-oncology where Bristol Myers Squibb appeared to hold a decisive lead. Inside Merck's research organization, there were serious discussions in 2011 about whether to continue investing in the program at all. The decision to press forward, accelerate development, and pursue a bold regulatory strategy of seeking approval in melanoma before completing standard Phase 3 trials is arguably the most consequential single R&D decision in modern pharmaceutical history. By fiscal year 2024, Keytruda alone generated approximately $29.5 billion in revenue — more than the entire annual sales of most Fortune 500 companies, more than the GDP of nations, and more than any single pharmaceutical product has ever produced in a year. It is approved across more than 40 cancer indications globally and is today used in approximately one-third of all new cancer treatment decisions in the United States.
That extraordinary commercial success has made Merck & Co. Simultaneously one of the most admired companies in the pharmaceutical industry and one of the most closely watched by investors tracking a specific date: 2028, when Keytruda's core U.S. Patent protection is scheduled to expire. The prospect of biosimilar competition in pembrolizumab — a biologic that will be substantially more difficult to replicate than a small-molecule pill but not impossible — raises the central strategic question that defines Merck's corporate agenda for this decade: can the company build a post-Keytruda growth engine large enough to absorb what analysts estimate could be a $15 to $20 billion annual revenue hole when biosimilar erosion reaches full force in the early 2030s?
Merck's answer to that question has cost approximately $50 billion in acquisitions and licensing deals since 2021, and the results are beginning to take shape in its pipeline. The $11.5 billion acquisition of Acceleron Pharma delivered sotatercept — approved by the FDA in March 2024 as Winrevair for pulmonary arterial hypertension and generating early commercial traction that analysts project could reach $3 to $5 billion annually by the late 2020s. The $10.8 billion acquisition of Prometheus Biosciences in 2023 added tulisokibart, a potential breakthrough in inflammatory bowel disease that could generate multi-billion-dollar sales if Phase 3 data replicate the remarkable Phase 2 results in Crohn's disease. And subcutaneous Keytruda — a reformulation that would allow patients to receive their pembrolizumab injection in minutes rather than hours, extending effective patent life and reducing the convenience argument for biosimilar switching — is moving through trials that could reshape the post-2028 competitive dynamic entirely.
With $63.6 billion in fiscal year 2024 revenue, approximately 74,000 employees, and a market capitalization of approximately $215 billion that has been compressed by patent-cliff fears from a peak exceeding $330 billion in late 2023, Merck stands at an inflection point that will determine whether it joins the ranks of pharmaceutical companies that successfully navigated their blockbuster cliff — AbbVie's Humira succession is the most recent example — or whether it endures a decade of revenue compression and investor disappointment. The answer will be determined not primarily by the drugs Merck has already approved, but by the clinical trials reading out in the next 36 months.
How Merck & Co., Inc. Makes Money
Merck & Co.'s business model is, at its most fundamental level, a high-fixed-cost, high-margin research enterprise that bets billions of dollars on the ability of its scientists to discover, develop, and win regulatory approval for new medicines before the patent-protected exclusivity on its current drugs expires. The pharmaceutical industry's economics are unusual and widely misunderstood outside the sector: the cost of bringing a single new molecular entity to market — accounting for the 90-plus percent failure rate across all compounds that enter clinical development — is estimated by the Tufts Center for the Study of Drug Development at approximately $2.6 billion per approved drug when fully loaded capital costs and time value of money are included. In return for accepting that extraordinary financial risk and 10-to-15-year development timeline, pharmaceutical companies receive 20-year patent protection from the date of filing, plus supplementary protections including regulatory data exclusivity and, for biologics like Keytruda, 12 years of biosimilar exclusivity in the United States. Merck's entire enterprise — its manufacturing infrastructure across more than 30 countries, its global commercial organization in 140-plus markets, its research and development investment of approximately $16.4 billion in fiscal year 2024 — is organized around maximizing the returns from this patent window and then replacing them with the next generation of protected products before the window closes.
The Pharmaceutical segment, which generated approximately $57.6 billion of Merck's total $63.6 billion in fiscal year 2024 revenue, is heavily concentrated in oncology. Keytruda — a programmed death-1 (PD-1) receptor blocking antibody that restores the immune system's ability to recognize and attack cancer cells — is not merely Merck's largest product but one of the most medically transformative drugs in oncology history. It is approved across more than 40 distinct cancer indications globally, including melanoma, non-small cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, cervical cancer, hepatocellular carcinoma, colorectal cancer, and a tissue-agnostic indication covering tumors with high microsatellite instability regardless of their anatomical origin. No drug in pharmaceutical history has ever been approved across so many distinct cancer types, and the clinical trial program supporting those approvals — which as of early 2025 encompasses more than 1,600 active clinical studies involving more than 300,000 patients globally — represents the most extensive single-drug trial program ever conducted. The commercial organization supporting Keytruda spans more than 100 countries, and the drug's global market share in first-line non-small cell lung cancer — the single largest oncology indication — exceeds 50 percent in the United States.
The pricing power underlying Keytruda's revenue is substantial and structurally embedded. In the United States, a full year of Keytruda therapy for a single patient can cost between $150,000 and $200,000 at list price depending on the indication and dosing schedule, with actual net prices after rebates and discounts typically in the $90,000 to $130,000 range. These prices are supported by clinical evidence of life extension and cure in patient populations where alternatives are far less effective or entirely absent, by the payer dynamics of oncology coverage where commercial insurers and Medicare generally cover approved indications, and by the absence of biosimilar competition that will eventually arrive after 2028 but is not yet a commercial reality. The consequence is gross margins on Keytruda that consistently exceed 75 percent — among the highest margin profiles in the global pharmaceutical industry.
Beyond Keytruda, the Pharmaceutical segment generates meaningful revenue from several additional franchises. Gardasil and Gardasil 9 generated approximately $7.8 billion in fiscal year 2024 — a decline from prior years driven primarily by a sharp Chinese procurement pullback — and represent the global standard of care in HPV cancer prevention across more than 100 national immunization programs. Winrevair (sotatercept), approved by the FDA in March 2024 for pulmonary arterial hypertension, generated over $500 million in its first partial year of sales and is expected to grow substantially as global approvals and prescriber adoption expand. The cardiovascular and metabolic portfolio — led by the DPP-4 inhibitor Januvia — continued to face structural competitive headwinds from GLP-1 receptor agonists, with the sitagliptin franchise declining toward approximately $2 billion and expected to continue eroding as biosimilar and therapeutic competition intensifies.
The Animal Health segment, which generated approximately $5.8 billion in fiscal year 2024, operates on a different and in some ways more stable business model than human pharmaceuticals. Merck Animal Health is the world's second-largest animal health company and supplies vaccines, anti-infectives, antiparasitic products, and biologics for companion animals and livestock globally. The companion animal business — led by the Bravecto flea and tick prevention product and the Librela canine pain management monoclonal antibody — is the higher-margin and faster-growing component, benefiting structurally from the pet humanization trend that has increased per-pet veterinary spending substantially in developed markets. The livestock business generates volume at lower margins, serving protein production industries whose capex cycles are driven by commodity prices and public health biosecurity requirements.
Across both segments, Merck's revenue model is powerfully skewed toward high-margin prescription sales in the United States, which alone generates more than half of total company revenue and an even higher proportion of operating profit, reflecting the substantially higher drug prices the U.S. Market allows relative to price-controlled European, Japanese, and emerging market systems. Merck invested approximately $16.4 billion in research and development in fiscal year 2024 — approximately 26 percent of net sales — one of the highest R&D intensity ratios in the large-cap pharmaceutical peer group, reflecting the company's urgent need to fill the post-Keytruda pipeline with approved products generating revenue before the patent cliff arrives and the Keytruda cash engine begins to slow.
Merck's manufacturing and supply chain infrastructure represents a substantial competitive asset that is often overlooked in financial analysis focused on R&D pipelines. The company operates biologics manufacturing facilities in the United States, Germany, Ireland, and Singapore, and its ability to manufacture pembrolizumab at the scale required to supply 40-plus oncology indications globally — approximately 450,000 patients receiving Keytruda treatment at any given time — represents a production and quality management capability that took more than a decade of capital investment and regulatory qualification to build. Any biosimilar competitor seeking to enter the pembrolizumab market must not only replicate the molecule's structural characteristics within acceptable biosimilarity standards but also build or contract manufacturing capacity capable of supplying a global patient population, a barrier that substantially increases the capital required for biosimilar entry and limits the number of companies that can credibly attempt it. Biologic manufacturing is one of the least visible but most durable elements of Merck's competitive moat, and its capacity investments — which have expanded significantly since 2018 to support Keytruda's global rollout — will also accommodate the next generation of biologic products as the pipeline matures toward approval. The company's global commercial infrastructure — spanning dedicated oncology sales forces, vaccine access teams, and animal health specialists across more than 140 countries — represents a distribution and market access capability built over decades that newcomers cannot replicate through financial investment alone, and that will remain valuable regardless of which specific products Merck's pipeline delivers to market in the years ahead.
Merck & Co., Inc. Revenue and Financial Performance
Merck & Co.'s fiscal year 2024 financial results reflected the extraordinary commercial power of the Keytruda franchise operating at peak — and the building investment pressure required to construct a pipeline capable of sustaining that revenue base after 2028. Total revenue of approximately $63.6 billion represented growth of approximately 7 percent from fiscal year 2023's $58.5 billion, with the Pharmaceutical segment driving essentially all the growth through Keytruda's continued global penetration and the initial commercial contribution of Winrevair following its March 2024 FDA approval. Keytruda alone — at approximately $29.5 billion — grew approximately 21 percent year over year, a rate that is remarkable for a drug already generating more annual revenue than most Fortune 500 companies.
Gardasil's performance created a partial offset, declining approximately 12 percent to approximately $7.8 billion as Chinese government procurement remained substantially below prior-year levels. The China Gardasil situation illustrates a structural vulnerability in Merck's otherwise formidable vaccine franchise: a single government's procurement decision can shift hundreds of millions of dollars of quarterly revenue with almost no warning, and the concentration of global HPV vaccine revenue in a relatively small number of national immunization programs creates geopolitical risk that standard pharmaceutical competitive analysis does not fully capture.
Operating cash flow for fiscal year 2024 reached approximately $19.7 billion, with free cash flow of approximately $17.3 billion after capital expenditures — figures that reflect Keytruda's extraordinary cash generative power at current scale. Merck deployed approximately $16.4 billion in research and development during fiscal year 2024, approximately 26 percent of net sales, one of the highest research intensity ratios in large-cap pharmaceuticals. The company returned approximately $13.3 billion to shareholders through dividends and share repurchases, maintaining its position as a reliable income stock while funding one of the most aggressive pharmaceutical business development campaigns in industry history. Net income reached approximately $15.6 billion, with adjusted non-GAAP earnings per share of approximately $7.65, reflecting continued operational discipline even as total R&D and business development spending reached record levels. The balance sheet at year-end 2024 reflected net debt of approximately $14 billion, elevated from prior years by the approximately $22 billion deployed in the Prometheus and Acceleron acquisitions and various licensing payments. Management has guided toward deleveraging to approximately 1.5 times net debt to EBITDA over the following two to three years, funded by Keytruda's substantial free cash flow generation in its remaining patent-protected years — a financial plan that requires no heroic pipeline assumptions to execute.
Competitive Advantage
Merck's most formidable competitive advantage is the Keytruda franchise's compounding clinical and commercial momentum — a phenomenon where each new approved indication generates a body of clinical evidence, an experienced oncology sales force relationship, and a patient outcome data set that reinforces the drug's clinical credibility and market share in subsequent indications. Pembrolizumab's dominance in first-line non-small cell lung cancer — the single largest oncology indication globally — creates a commercial gravitational pull in which oncologists who prescribe Keytruda for lung cancer patients are then systematically presented with Keytruda clinical data in melanoma, bladder cancer, head and neck cancer, and dozens of other tumor types, compounding market penetration across the oncology franchise rather than requiring independent market creation for each indication.
The clinical trial network Merck has constructed around Keytruda is arguably the most significant competitive moat in the pharmaceutical industry today and one that will endure well beyond the patent expiration date. With more than 1,600 active clinical studies, Merck has established relationships with oncology researchers and academic medical centers on every inhabited continent — a platform that generates ongoing clinical evidence, deepens physician engagement with pembrolizumab, and provides first-mover research access to combination therapy opportunities that could create new standard-of-care regimens even after biosimilar entry into the IV formulation market. The cost to a competitor of replicating this clinical infrastructure — in financial terms, in regulatory relationships, and in the academic medical center relationships required to recruit patients — would realistically run into the tens of billions of dollars and require more than a decade of investment before generating comparable clinical credibility.
The regulatory approval portfolio itself constitutes an additional layer of competitive protection. Each of Keytruda's 40-plus approved indications carries its own regulatory approval, its own product label, and its own reimbursement coverage negotiation across hundreds of national and regional payer systems globally. A biosimilar manufacturer entering the market after 2028 will automatically receive the ability to compete on pembrolizumab's existing approved indications — biosimilar approvals are indication-inclusive under U.S. Regulatory rules — but any new indications that Merck obtains through its ongoing clinical program between now and biosimilar entry will come with separate patent protection, separate label language, and potential formulary positioning advantages that biosimilar manufacturers cannot immediately contest.
In animal health, Merck's competitive advantage rests on two mutually reinforcing foundations: the breadth and scientific depth of its vaccine portfolio in livestock — where preventing infectious disease is economically far more valuable than treating it — and the rapidly growing companion animal portfolio anchored by Bravecto's parasite prevention leadership and Librela's novel mechanism in canine pain management. Librela, a monoclonal antibody targeting nerve growth factor approved in the U.S. In 2023, is the first entirely new mechanism of action for veterinary pain management in more than a decade and represents the kind of biologic innovation that pure-play animal health competitors — who lack the antibody engineering expertise embedded in Merck's human pharmaceutical research organization — cannot easily replicate. This application of human pharmaceutical research capabilities to veterinary medicine creates a durable innovation advantage that is structural rather than dependent on any specific product's commercial performance. Merck's scientific reputation — built over 130 years and anchored by innovations from the first commercially available statin to the hepatitis B vaccine to the cancer immunotherapy revolution — also provides a less quantifiable but genuinely meaningful competitive advantage in recruiting research talent and forming academic and government partnerships. The ability to attract oncologists, immunologists, and drug developers who want their work to reach the highest-impact platform available is a compounding talent advantage that reinforces the clinical trial execution quality and scientific credibility that commercial success requires.
Challenges and Risks
The defining challenge facing Merck & Co. Is one of the most quantitatively predictable risks in corporate history: the expiration of Keytruda's primary U.S. Composition-of-matter patent in 2028, which will open the door to biosimilar competition in pembrolizumab and expose approximately $29.5 billion of annual revenue — roughly 46 percent of total company revenue as of fiscal year 2024 — to competitive erosion. Biosimilar biologics do not erode as rapidly as small-molecule generic drugs, because their complexity makes exact replication difficult and because prescribers and patients tend to exhibit higher inertia around injectable cancer therapies than around oral pills. The erosion curve for a biologic blockbuster after biosimilar entry typically runs over 5 to 8 years rather than the 12-to-18-month collapse seen in small-molecule generics. But even at a conservative 30 percent market share loss by 2033, Merck would be facing a revenue gap measured in the tens of billions of dollars — a hole that no pharmaceutical company in history has successfully filled with organic pipeline alone. AbbVie's experience with Humira provides a cautionary but ultimately instructive comparison: Humira's biosimilar entry in the U.S. In 2023 drove approximately 30 percent revenue decline in that franchise, but AbbVie had constructed a successor franchise in Skyrizi and Rinvoq that generated combined revenue exceeding $15 billion in 2024 and is growing rapidly. The Merck question is whether Winrevair, tulisokibart, subcutaneous Keytruda, and the rest of its pipeline can do for Merck what Skyrizi and Rinvoq did for AbbVie.
Geographic concentration risk intensified in 2023 and 2024 as China — which had been the largest international growth market for Gardasil — abruptly reduced procurement volumes following domestic policy decisions and apparent diplomatic considerations. Gardasil revenue from China, which had exceeded $3 billion annually at peak, declined precipitously and introduced a level of political risk into Merck's vaccine business that management had not previously needed to price into its growth forecasts. More broadly, the Chinese government's increasing preference for domestic pharmaceutical products and its ability to exercise procurement leverage creates uncertainty around Merck's long-term revenue trajectory in a market of 1.4 billion people.
Pricing pressure in the United States escalated in a structurally new way with the implementation of Medicare drug price negotiation provisions under the Inflation Reduction Act of 2022. The IRA gives the Centers for Medicare & Medicaid Services authority to negotiate prices directly with pharmaceutical manufacturers for high-expenditure Medicare Part D drugs, with negotiated prices taking effect beginning in 2026. Sitagliptin — the active ingredient in Merck's Januvia and Janumet — was among the first ten drugs selected for negotiation in 2023, with a negotiated price that represented a reduction of approximately 79 percent from the list price. While sitagliptin is already in revenue decline due to GLP-1 competition, the IRA's expansion of negotiation authority to additional drugs each year raises the risk that Keytruda itself will become subject to negotiation, which would have materially larger revenue implications. Merck has been one of the most aggressive pharmaceutical companies in legally challenging the IRA's negotiation provisions, filing suit arguing the program violates the First Amendment and Fifth Amendment, though the industry's legal prospects are uncertain.
Pipeline execution risk — the ever-present pharmaceutical industry challenge of clinical trial failure — is particularly acute given the magnitude of Merck's pipeline investment and the compressed timeline before the Keytruda cliff arrives. Tulisokibart's Phase 2 results in Crohn's disease were genuinely impressive, with remission rates that exceeded competitive benchmarks, but Phase 2 data routinely overestimate Phase 3 outcomes in inflammatory bowel disease, and a Phase 3 failure would remove one of the largest anticipated contributors to Merck's post-2028 revenue bridge.
Growth Strategy
Merck's growth strategy under CEO Robert M. Davis is organized around four interconnected priorities: maximizing Keytruda's remaining patent-protected commercial window, commercially executing Winrevair's global launch, advancing the business development-sourced pipeline toward regulatory approval, and building new disease area franchises through both internal research and external partnership.
On Keytruda maximization, the strategy involves pursuing additional indications — particularly in earlier-stage cancers where the drug is being evaluated as adjuvant therapy following surgery, theoretically expanding the eligible patient population far beyond the metastatic patients who represent its current core — while simultaneously advancing subcutaneous formulation to protect the franchise post-2028. The adjuvant strategy is particularly significant: Keytruda is already approved as adjuvant therapy in melanoma, renal cell carcinoma, and non-small cell lung cancer, and its ongoing trials in earlier-stage colon cancer, bladder cancer, and gastric cancer could substantially broaden the treated population and extend the revenue life of the franchise independent of biosimilar dynamics.
On business development, Merck's most significant recent commitment was the 2023 collaboration with Daiichi Sankyo of Japan — a deal valued at up to $22 billion including milestone payments — to co-develop and co-commercialize multiple antibody-drug conjugate candidates across oncology indications. Antibody-drug conjugates, which combine the targeting precision of monoclonal antibodies with the cell-killing potency of cytotoxic chemotherapy payloads, represent the fastest-growing class in oncology and the natural complement to Keytruda in combination treatment strategies. The Daiichi Sankyo partnership effectively buys Merck a meaningful position in next-generation oncology without requiring it to build an internal ADC manufacturing and chemistry capability from scratch.
Merck has also explicitly flagged cardiometabolic disease and infectious disease as growth areas where business development is actively targeted. In cardiometabolic disease, following the GLP-1-driven disruption of its diabetes franchise, Merck is evaluating compounds targeting obesity-related conditions, kidney disease, and heart failure through a mix of internal programs and external licensing arrangements. In infectious disease — a category where Merck has historical strength from its HIV and hepatitis programs, and where its oral COVID-19 antiviral molnupiravir provided a recent proof of concept in pandemic response — the company sees continued opportunity in novel antivirals and next-generation vaccines. Together, these business development priorities represent a deliberate effort to build a portfolio broad enough that the post-2028 revenue trajectory does not depend on any single pipeline success. The breadth of this business development agenda reflects a clear-eyed strategic judgment that diversification across disease areas, mechanisms of action, and development stages is the best available hedge against the binary uncertainty of clinical trial outcomes in the time window before the Keytruda patent cliff.
Future Outlook
Merck's medium-term future is inextricably linked to three parallel races: the commercial ramp of Winrevair in pulmonary arterial hypertension, the Phase 3 clinical data trajectory of tulisokibart in inflammatory bowel disease, and the outcome of the subcutaneous Keytruda program — each of which will substantially shape the company's revenue and valuation trajectory into the early 2030s.
Winrevair's early commercial performance has been encouraging. The drug launched in a disease area with approximately 50,000 to 100,000 patients in the United States alone, a specialist prescriber base of approximately 3,000 PAH physicians who are among the most data-literate and therapeutically aggressive in medicine, and a payer environment that has historically been willing to cover expensive therapies for a disease without good alternatives. Analyst consensus projects Winrevair peak annual sales in the range of $3 to $5 billion, which would make it a meaningful but insufficient standalone Keytruda replacement, requiring the broader pipeline to contribute complementary revenue at scale.
Tulisokibart's Phase 3 program in Crohn's disease represents the higher-stakes bet in the pipeline. The Phase 2 data that justified Merck's $10.8 billion Prometheus acquisition showed remission rates substantially above the benchmark established by existing approved biologics including AbbVie's Skyrizi and Johnson & Johnson's Tremfya, raising analyst projections for the drug's commercial potential to $5 billion or more annually if Phase 3 data replicate the Phase 2 signal. An IBD drug of that scale would establish a second major disease area franchise alongside oncology and would meaningfully diversify Merck's revenue away from its current near-total dependence on Keytruda.
Subcutaneous Keytruda — the reformulation allowing pembrolizumab injection in approximately five minutes rather than 30-minute intravenous infusion — could be the most commercially consequential near-term development if Phase 3 results and commercial execution align favorably. The new formulation would carry its own patent protection extending into the 2030s, meaningfully complicating the biosimilar substitution decision even after IV formulation patents expire, and management has indicated that subcutaneous Keytruda could capture a majority of new pembrolizumab patients following approval. The sum of these three programs — if each succeeds — would represent a credible post-2028 revenue bridge rather than a speculative hope. Beyond these three near-term catalysts, management has identified a portfolio of earlier-stage assets across oncology, cardiometabolic disease, and infectious disease that represents the next layer of the post-2028 revenue bridge — a portfolio intentionally built with sufficient breadth that no single clinical failure is capable of invalidating the entire succession strategy.
